 |
| |
| May-23-19 | Upgrade |
Citigroup |
Neutral → Buy |
|
|
| May-21-19 | Initiated |
Credit Suisse |
Outperform |
$208 |
|
| Jan-28-19 | Downgrade |
Evercore ISI |
Outperform → In-line |
|
|
| Oct-01-18 | Initiated |
Cantor Fitzgerald |
Neutral |
$223 |
|
| Apr-05-18 | Reiterated |
Barclays |
Equal Weight |
$190 → $180 |
|
| Feb-12-18 | Reiterated |
Mizuho |
Buy |
$192 → $200 |
|
| Jan-23-18 | Upgrade |
Argus |
Hold → Buy |
|
|
| Nov-01-17 | Downgrade |
Argus |
Buy → Hold |
|
|
| Oct-26-17 | Reiterated |
RBC Capital Mkts |
Sector Perform |
$192 → $188 |
|
| Sep-28-17 | Reiterated |
Mizuho |
Buy |
$183 → $198 |
|
| Sep-15-17 | Initiated |
RBC Capital Mkts |
Sector Perform |
$192 |
|
| Jul-11-17 | Resumed |
Jefferies |
Buy |
|
|
| Jun-23-17 | Initiated |
Deutsche Bank |
Hold |
$172 |
|
| Apr-05-17 | Downgrade |
Jefferies |
Buy → Hold |
|
|
| Mar-09-17 | Initiated |
UBS |
Neutral |
$185 |
|
| Feb-01-17 | Upgrade |
BofA/Merrill |
Neutral → Buy |
|
|
| Dec-20-16 | Downgrade |
Credit Suisse |
Outperform → Neutral |
|
|
| Dec-13-16 | Initiated |
Oppenheimer |
Outperform |
|
|
| Nov-08-16 | Initiated |
Mizuho |
Buy |
$164 |
|
| Aug-26-16 | Initiated |
Gabelli & Co |
Hold |
|
|
|
|
| Jun-24-19 10:27AM | Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids Zacks |
| Jun-22-19 09:33AM | This would be the worst-case scenario for health stocks, according to UBS MarketWatch |
| Jun-21-19 09:15AM | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks |
| Jun-20-19 05:50PM | Amgen (AMGN) Gains But Lags Market: What You Should Know Zacks |
| 09:45AM | The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara Zacks |
| Jun-19-19 04:00PM | Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership PR Newswire |
| 11:49AM | 3 Large-Cap Biotech Stocks to Buy for Massive Gains InvestorPlace |
| 11:04AM | The Zacks Analyst Blog Highlights: Broadcom, Amgen, NVIDIA, Bristol-Myers and Restaurant Brands Zacks |
| 10:29AM | Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data Zacks |
| 10:21AM | Merck's Keytruda Gets 2nd Label Expansion Approval in June Zacks |
| 09:06AM | Big Drugmakers That May Tread the M&A Path After Pfizer Zacks |
| Jun-18-19 01:00PM | Top Analyst Reports for Broadcom, Amgen & NVIDIA Zacks |
| 08:03AM | Roche's Rozlytrek Gets Approval in Japan for Solid Tumors Zacks |
| 08:00AM | Looking For Great Stocks? First Use A Checklist To Identify Great Bases Investor's Business Daily |
| 08:00AM | 3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal Motley Fool |
| 07:09AM | Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch |
| Jun-16-19 02:00AM | Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019 PR Newswire |
| Jun-14-19 05:48PM | UPDATE 1-U.S. drugmakers file lawsuit against requiring drug prices in TV ads Reuters |
| 03:14PM | U.S. drugmakers file lawsuit against rule requiring drug prices in TV ads Reuters |
| 08:47AM | The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA Benzinga |
| 08:34AM | Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti Zacks |
| 05:19AM | Drugmakers sue to stop rule requiring prices in TV ads Financial Times |
| Jun-13-19 07:13PM | FDA Approves Amgen And Allergan's KANJINTI (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab) PR Newswire |
| 05:40PM | Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris Zacks |
| 04:12PM | Amgen, Biogen, Gilead and Novo Nordisk have very high capacity for M&A, says Moodys MarketWatch |
| 09:36AM | Ligand Inks Oncology Drug Discovery Deal With PhoreMost Zacks |
| 09:31AM | Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock Zacks |
| Jun-12-19 06:33PM | Roche's Rituxan Gets Priority Review for Blood Disorder Zacks |
| 05:50PM | Amgen (AMGN) Gains As Market Dips: What You Should Know Zacks |
| 09:00AM | Amgen Publishes Offer Document With Respect To The Recommended Public Cash Offer To The Shareholders Of Nuevolution PR Newswire |
| 08:33AM | Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer Zacks |
| Jun-11-19 09:54AM | Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II Zacks |
| Jun-10-19 09:39AM | Roche Receives FTC Request for Further Data on Spark Buyout Zacks |
| Jun-07-19 04:00PM | Amgen To Present At The Goldman Sachs 40th Annual Global Healthcare Conference PR Newswire |
| 09:59AM | Mirati Therapeutics Stock Will Fall From Here, Analyst Says Barrons.com |
| Jun-06-19 05:59PM | Is Amgen, Inc. (AMGN) A Good Stock To Buy? Insider Monkey |
| 05:50PM | Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know Zacks |
| 03:13PM | 5 Healthcare Stocks to Pick Up From the Wreckage InvestorPlace |
| 02:30PM | Should We Be Delighted With Amgen Inc.'s (NASDAQ:AMGN) ROE Of 75%? Simply Wall St. |
| 09:22AM | Lilly's Emgality Gets FDA Approval for Cluster Headache Zacks |
| 09:09AM | Was ASCO Quieter for Big Drug/Biotech Stocks This Year? Zacks |
| Jun-05-19 01:07PM | Amgen Cancer Treatment Candidate Had 'Adverse Events' in Almost Half of Patients TheStreet.com |
| 09:05AM | Pfizer to Launch Several Drugs Despite Generic Headwinds Zacks |
| 08:00AM | Iovance and Amgen Are Making Cancer History Bloomberg |
| 07:32AM | Amgen's early-stage study of cancer treatment had 'adverse events' in nearly half of its patients MarketWatch |
| 07:00AM | Amgen Highlights the Versatility of the BiTE® Immuno-Oncology Platform in Multiple Tumour Types at ASCO 2019 CNW Group |
| 07:00AM | Amgen Announces First Clinical Data Evaluating Investigational KRAS(G12C) inhibitor AMG 510 at ASCO 2019 CNW Group |
| Jun-04-19 06:45PM | Amgen Drug Breaks New Ground GuruFocus.com |
| 05:06PM | FDA approves Lilly's migraine drug as first ever cluster headache treatment Reuters |
| 12:37PM | Amgens Good News on Lung Cancer Boosted Mirati Therapeutics. Heres What Wall Street Is Saying. Barrons.com |
| 11:50AM | Sanofi loses German patent case against Amgen over cholesterol drug Reuters |
| 10:53AM | How Does Mirati's Lung Cancer Candidate Stack Up Against Amgen's? Benzinga |
| 10:19AM | Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity Zacks |
| 09:30AM | Company News For Jun 4, 2019 Zacks |
| 09:21AM | 3 Cancer Stocks Given a Lift by Amgen Motley Fool |
| Jun-03-19 05:04PM | US STOCKS-Nasdaq confirms correction as Facebook, Alphabet, Amazon drag Reuters |
| 04:30PM | Amgen and PHV rise while Alphabet and Centene slip Associated Press |
| 04:24PM | Did This Biotech Giant Just Find The Key To An 'Undruggable' Protein? Investor's Business Daily |
| 03:25PM | US STOCKS-Wall Street falls as Facebook, Alphabet, Amazon drag Reuters |
| 02:46PM | Why Cancer-Fighting Stocks & ETFs Are Soaring Zacks |
| 01:40PM | US STOCKS-Wall Street tumbles as Facebook, Alphabet extend slide Reuters |
| 12:47PM | Amgen Stock Jumps on Promising Cancer Drug Trial Results Barrons.com |
| 12:18PM | Here's Why Mirati Therapeutics Is Jumping Today Motley Fool |
| 11:35AM | Amgen Shares Gain on Positive Lung-Cancer Trial Results TheStreet.com |
| 11:17AM | US STOCKS-Wall St edges higher, boosted by healthcare; Alphabet, Amazon pressure Nasdaq Reuters |
| 11:11AM | Amgen drug shows high response rate in small lung and colon cancer trial Reuters |
| 09:28AM | Amgen drug shows high response rate in small lung and colon cancer trial Reuters |
| 09:01AM | Amgen Charts Indicate Bounce Possible Within a Longer-Term Downtrend TheStreet.com |
| 09:00AM | Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019 PR Newswire |
| 05:32AM | Amgen Rises 3% Investing.com |
| Jun-02-19 09:00PM | Amgen drug takes aim at cancer master switch Financial Times |
| 10:45AM | Amgen Highlights The Versatility Of The BiTE® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019 PR Newswire |
| Jun-01-19 11:37AM | The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace Benzinga |
| May-31-19 05:45PM | Amgen (AMGN) Dips More Than Broader Markets: What You Should Know Zacks |
| 01:04PM | What to watch at the world's largest cancer conference CNBC Videos |
| 12:32PM | What to expect from the ASCO annual conference Yahoo Finance Video |
| May-30-19 03:11PM | Ranking the Top 10 Stock Buybacks of Last Year InvestorPlace |
| 09:31AM | Amgen (AMGN) Down 4% Since Last Earnings Report: Can It Rebound? Zacks |
| 08:28AM | Amarin Rises on Priority Review for Vascepa Label Expansion Zacks |
| May-29-19 04:00PM | Amgen To Webcast Investor Meeting At 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO) PR Newswire |
| 03:29PM | Merck (MRK) Up This Year So Far: Will the Momentum Continue? Zacks |
| 10:22AM | Biotech Stock Roundup: AMGN's Nuevolution Buyout, CELG, INCY Drugs' Label Expansion Zacks |
| 02:00AM | Additional Irrevocable Undertakings To Accept Amgen's Recommended Public Cash Offer To The Shareholders Of Nuevolution PR Newswire |
| May-28-19 04:00PM | Amgen Joins With Community Oncology Networks For New Research Collaboration PR Newswire |
| 11:30AM | British Columbia to be first Canadian province to switch patients to biosimilars Reuters |
| May-27-19 05:24PM | Canada's BC will be first province to switch patients to biosimilars Reuters |
| 01:24AM | 3 Peninsula biotech IPOs show off diversity of targets, seek to raise more than $400 million American City Business Journals |
| May-26-19 09:00AM | 3 Charts Every Amgen Investor Needs to See Motley Fool |
| May-24-19 01:16PM | Final Trades: Amgen, Costco, The Communications Sector & Defense stocks CNBC Videos |
| May-23-19 12:47PM | Buy Amgen and Gilead Stock as Biotech Returns to Stability and Growth Barrons.com |
| 10:38AM | Amgen (AMGN) Offers to Acquire Drug Discovery Platform Zacks |
| May-22-19 10:14AM | Amgen To Buy Danish Collaborator Nuevolution For $167M Benzinga |
| 03:23AM | Amgen offers to buy Copenhagen-based Nuevolution for $167 mln Reuters |
| 02:00AM | Amgen announces a recommended public cash offer to the shareholders of Nuevolution PR Newswire |
| May-21-19 04:00PM | Amgen Announces Voting Results Of Annual Meeting Of Stockholders PR Newswire |
| 03:00PM | Apple, Biogen, Diamondback Energy and More: Why These Stocks Are Trending Insider Monkey |
| May-20-19 09:42AM | Medicines Company Rallies On Positive LDL Cholesterol Study Results Benzinga |
| 09:04AM | Ligand Grants Preclinical Candidate Rights to UK-based Firm Zacks |
| May-17-19 12:29PM | Who Had the Better Quarter: Gilead Sciences or Amgen? Motley Fool |
| 07:33AM | Bulls Make Money, Bears Make Money and Hogs Get Slaughtered, Jim Cramer Says TheStreet.com |
|
|
|
|
| Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; and DaVita Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| SUGAR RONALD D | Director | Jun 05 | Option Exercise | 54.71 | 2,000 | 109,420 | 16,219 | Jun 05 06:55 PM | | SUGAR RONALD D | Director | Jun 05 | Sale | 175.68 | 2,000 | 351,360 | 14,219 | Jun 05 06:55 PM | | SUGAR RONALD D | Director | May 01 | Option Exercise | 54.71 | 2,000 | 109,420 | 15,092 | May 03 05:37 PM | | SUGAR RONALD D | Director | May 01 | Sale | 175.73 | 2,000 | 351,460 | 13,092 | May 03 05:37 PM | | SUGAR RONALD D | Director | Apr 03 | Option Exercise | 54.71 | 2,000 | 109,420 | 15,092 | Apr 03 06:27 PM | | SUGAR RONALD D | Director | Apr 03 | Sale | 193.18 | 2,000 | 386,360 | 13,092 | Apr 03 06:27 PM | | SUGAR RONALD D | Director | Mar 06 | Option Exercise | 54.71 | 2,000 | 109,420 | 14,988 | Mar 08 07:47 PM | | SUGAR RONALD D | Director | Mar 06 | Sale | 188.88 | 2,000 | 377,760 | 12,988 | Mar 08 07:47 PM | | SUGAR RONALD D | Director | Feb 07 | Option Exercise | 54.71 | 2,000 | 109,420 | 14,988 | Feb 11 09:27 PM | | SUGAR RONALD D | Director | Feb 07 | Sale | 190.00 | 2,000 | 380,000 | 12,988 | Feb 11 09:27 PM | | Jacks Tyler | Director | Dec 06 | Option Exercise | 82.60 | 20,000 | 1,652,000 | 28,979 | Dec 10 08:46 PM | | Jacks Tyler | Director | Dec 06 | Sale | 195.41 | 20,000 | 3,908,232 | 8,979 | Dec 10 08:46 PM | | Piacquad David | SVP, Business Development | Nov 30 | Option Exercise | 54.69 | 6,500 | 355,485 | 45,128 | Dec 03 08:13 PM | | Patton Cynthia M | SVP & CCO | Nov 29 | Option Exercise | 54.69 | 1,777 | 97,184 | 23,090 | Dec 03 08:11 PM | | Patton Cynthia M | SVP & CCO | Nov 29 | Sale | 202.88 | 1,777 | 360,520 | 21,313 | Dec 03 08:11 PM | | HENDERSON REBECCA M | Director | Aug 10 | Option Exercise | 63.11 | 3,000 | 189,330 | 16,197 | Aug 14 08:29 PM | | Harper Sean E | EVP, Research & Development | Jul 16 | Sale | 195.71 | 1,525 | 298,458 | 56,082 | Jul 16 08:20 PM |
|
|
|
|
|
|
